Literature DB >> 30091223

Magnetic resonance imaging as a prognostic disability marker in clinically isolated syndrome: A systematic review.

Anne C Rahn1, Sascha Köpke2, Jan-Patrick Stellmann1, Insa Schiffmann1, Carsten Lukas3, Declan Chard4,5, Christoph Heesen1,6.   

Abstract

Magnetic resonance imaging (MRI) is the key prognostic tool in people with a clinically isolated syndrome (CIS). There is increasing interest in treating people following a CIS in the hope that conversion to multiple sclerosis (MS) will be prevented and future disability reduced. So far, the prognostic value of MRI for disability following a CIS has not been evaluated systematically. We systematically searched MEDLINE and EMBASE. Cohort studies were selected if they reported associations of MRI and disability following a CIS, included at least 50 people with a CIS at baseline, had at least 5 years of follow-up and obtained at least one structural MRI measurement (T1 lesions, T2 lesions, T1 contrast-enhancing lesions or brain atrophy). We assessed the studies for quality and rated the completeness of MRI reporting. In total, 13 studies were identified reporting on the following: T2 lesion number and volume, T2 infratentorial lesion number and volume, T1 contrast-enhancing lesions and grey matter fraction. T2 brain lesion number determined soon after the occurrence of a CIS was associated with disability progression after 5-7 years, with an increased risk when 10 or more lesions were present. Infratentorial lesions were also associated with a higher risk of subsequent disability. The number and distribution of MRI-visible lesions soon after a CIS are associated with disability later on, and may offer additional useful information when making treatment decisions in people with early MS. Further work is required to determine whether other measures have a higher predictive potential.
© 2018 John Wiley & Sons A/S. Published by John Wiley & Sons Ltd.

Entities:  

Keywords:  zzm321990MRIzzm321990; clinically isolated syndrome; disability; multiple sclerosis; prognosis; systematic review

Mesh:

Year:  2018        PMID: 30091223     DOI: 10.1111/ane.13010

Source DB:  PubMed          Journal:  Acta Neurol Scand        ISSN: 0001-6314            Impact factor:   3.209


  4 in total

1.  Immunotherapy for people with clinically isolated syndrome or relapsing-remitting multiple sclerosis: treatment response by demographic, clinical, and biomarker subgroups (PROMISE)-a systematic review protocol.

Authors:  Thomas Lehnert; Christian Röver; Sascha Köpke; Jordi Rio; Declan Chard; Andrea V Fittipaldo; Tim Friede; Christoph Heesen; Anne C Rahn
Journal:  Syst Rev       Date:  2022-07-01

2.  Study protocol for a randomised controlled trial of a web-based behavioural lifestyle programme for emPOWERment in early Multiple Sclerosis (POWER@MS1).

Authors:  Nicole Krause; Karin Riemann-Lorenz; Tanja Steffen; Anne Christin Rahn; Jana Pöttgen; Jan-Patrick Stellmann; Sascha Köpke; Tim Friede; Andrea Icks; Markus Vomhof; Herbert Temmes; Markus van de Loo; Stefan M Gold; Christoph Heesen
Journal:  BMJ Open       Date:  2021-02-16       Impact factor: 2.692

3.  Improving quality, affordability, and equity of multiple sclerosis care.

Authors:  Annette Langer-Gould; Shilpa Klocke; Brandon Beaber; Sonu M Brara; Julie Debacker; Oluwasheyi Ayeni; Allen S Nielsen
Journal:  Ann Clin Transl Neurol       Date:  2021-03-10       Impact factor: 4.511

4.  Infratentorial and spinal cord lesions: Cumulative predictors of long-term disability?

Authors:  Iris Dekker; Madeleine H Sombekke; Lisanne J Balk; Bastiaan Moraal; Jeroen Jg Geurts; Frederik Barkhof; Bernard Mj Uitdehaag; Joep Killestein; Mike P Wattjes
Journal:  Mult Scler       Date:  2019-08-02       Impact factor: 6.312

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.